Social anxiety is a very common disorder and is especially common among
individuals with substance abuse or dependence (substance use disorders [SUDs]). Several epidemiologic surveys have estimated the
prevalence of social anxiety disorder (also called social phobia) in the
general population to be between 3% and 13% (Kessler et al., 1994; Schneier et al., 1992). However, in SUD clinics, the rate
is significantly greater. Zimmermann and colleagues (2004) surveyed 150
individuals seeking treatment for an SUD in Switzerland, using the
clinician-administered Leibowitz Social Anxiety Scale
(LSAS), and found that 20% of the participants screened positive for
generalized social phobia and 42.6% screened positive for nongeneralized
social phobia. Myrick and Brady (1997) evaluated 158 individuals entering an
outpatient clinical treatment trial for cocaine dependence and found that 13%
met criteria for social anxiety disorder. Finally, of 159 individuals seeking
treatment for heroin dependence, 18% to 25% screened positive for social
anxiety disorder (Grenyer et al., 1992).
In addition to social anxiety being prevalent in the drug treatment setting,
addiction is also commonly found in anxiety treatment clinics and may be
responsible for resistance to traditional anxiety disorder treatments (Coplan et al., 1993). In Australia, 146 individuals seeking
treatment for either social phobia or panic disorder at an anxiety treatment
program were evaluated (Page and Andrews, 1996). The researchers hypothesized
that they would see higher rates of sedative-hypnotic abuse and dependence
among the participants with panic disorder and higher rates of alcohol misuse
among the individuals with social phobia. They found, however, that both the
participants with social phobia and those with panic disorder had a rate of
sedative-hypnotic misuse that was eight times that of the general population.
Also, only the participants with social phobia had elevated rates of an alcohol
use disorder (Page and Andrews, 1996).
When two disorders co-occur, like social anxiety disorder
and addiction, causality (if it exists) is often difficult to unravel.
For example, chronic alcohol or illicit drug use can be anxiogenic.
Some treatment providers would argue that if an individual with an anxiety
disorder and co-occurring substance dependence has successful treatment for the substance dependence, recovering into a
sober lifestyle, their anxiety disorder will also be ameliorated. This line of
reasoning would be based on the assumption that the substance dependence
preceded the anxiety disorder and the direction of causality would be from
addiction to anxiety. As a disorder co-occurring with substance dependence,
social anxiety disorder most likely does not fit into these assumptions. The
average age of onset of social anxiety disorder is in the mid-teens (Schneier et al., 1992), at a time when social interpersonal
attitudes and relationships are being formed--also a time when experimentation
with illicit drugs and alcohol generally would begin. The average age of
alcohol dependence, for example, is roughly a decade later, in the mid-20s (Schuckit et al., 1998), making the direction of causality,
if it exists, more likely to be from social anxiety to substance dependence.
1 . Ballenger JC, Davidson JT, Lecrubier Y et al.
(1998), Consensus statement on social anxiety disorder from the International
Consensus Group on Depression and Anxiety. J Clin
Psychiatry 59(suppl 17):54-60.
2. Book SW, Randall CL (2002), Social anxiety disorder and alcohol use. Alcohol
Res Health 26(2):130-135.
3 . Coplan JD, Tiffon L,
Gorman JM (1993), Therapeutic strategies for the patient with
treatment-resistant anxiety. J Clin Psychiatry 54(suppl):69-74.
4. Davidson JR, Ford SM, Smith RD, Potts NL (1991), Long-term treatment of
social phobia with clonazepam. J Clin
5. Grenyer BF, Williams G, Swift W, Neill O (1992),
The prevalence of social-evaluative anxiety in opioid
users seeking treatment. Int J Addict 27(6):665-673.
6. Kalivas PW (2001), Drug addiction: to the cortex
and beyond! Am J Psychiatry 158(3):349-350 [editorial].
7. Kash SF, Tecott LH,
Hodge C, Baekkeskov S (1999), Increased anxiety and
altered responses to anxiolytics in mice deficient in
the 65-kDa isoform of glutamic
acid decarboxylase. Proc Natl
Acad Sci U S A 96(4):1698-1703.
8. Kessler RC, McGonagle KA, Zhao S et al. (1994),
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the
United States. Results from the National Comorbidity
Survey. Arch Gen Psychiatry 51(1):8-19.
9. Kranzler HR, Burleson JA, Brown J, Babor TF (1996), Fluoxetine
treatment seems to reduce the beneficial effects of cognitive-behavioral
therapy in type B alcoholics. Alcohol Clin Exp Res 20(9):1534-1541.
10. Li D, Chokka P, Tibbo P
(2001), Toward an integrative understanding of social
phobia. J Psychiatry Neurosci 26(3):190-202.
11. Malcolm RJ (2003), GABA systems, benzodiazepines, and
substance dependence. J Clin Psychiatry 64(suppl 3):36-40.
12. Myrick H, Brady KT (1997), Social phobia in cocaine-dependent individuals. Am J Addict 6(2):99-104.
13. Page AC, Andrews G (1996), Do specific anxiety disorders show specific drug
problems? Aust N Z J Psychiatry 30(3):410-414.
14. Pande AC, Davidson JR, Jefferson JW et al. (1999),
Treatment of social phobia with gabapentin: a
placebo-controlled study. J Clin Psychopharmacol
15. Pande AC, Feltner DE,
Jefferson JW et al. (2004), Efficacy of the novel anxiolytic
pregabalin in social anxiety disorder: a
placebo-controlled, multicenter study. J Clin Psychopharmacol
16. Pettinati HM, Volpicelli
JR, Kranzler HR et al. (2000), Sertraline
treatment for alcohol dependence: interactive effects of medication and
alcoholic subtype. Alcohol Clin Exp Res 24(7):1041-1049 [see comment].
17 . Randall CL, Johnson MR, Thevos AK et
al. (2001), Paroxetine for social anxiety
and alcohol use in dual-diagnosed patients. Depress Anxiety 14(4):255-262.
18. Schneier FR, Johnson J, Hornig CD et al. (1992),
Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen
19. Schuckit MA, Daeppen JB,
Tipp JE et al. (1998), The clinical course of
alcohol-related problems in alcohol dependent and nonalcohol
dependent drinking women and men. J Stud Alcohol 59(5):581-590.
20. Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990), Anxiety disorders in patients with
Parkinson's disease. Am J Psychiatry 147(2):217-220
21. Stork O, Ji FY, Obata K (2002),
Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a
conditioned fear stimulus. Neurosci Lett 327(2):138-142.
22. Stork O, Yamanaka H, Stork S et al. (2003), Altered conditioned fear
behavior in glutamate decarboxylase 65 null mutant
mice. Genes Brain Behav 2(2):65-70.
23. Tiihonen J, Kuikka J,
Bergstrom K et al. (1997), Dopamine reuptake site densities in patients with
social phobia. Am J Psychiatry 154(2):239-242.
24. Van Ameringen M, Mancini C, Pipe B et al. (2004), An open trial of topiramate in the
treatment of generalized social phobia. J Clin
25. Zimmermann G, Pin MA, Krenz S et al. (2004),
Prevalence of social phobia in a clinical sample of drug dependent patients. J
Affect Disord 83(1):83-87.